Skip to content

 

NEW YORK, Nov.  20, 2026 – This morning, the National Institute of Allergy and Infectious Diseases (NIAID) published the long-overdue Notices of Funding Opportunity (NOFOs) for the National Institutes of Health (NIH) HIV/AIDS Clinical Trials Networks: Leadership and Operations Centers, Laboratory Centers, Statistical and Data Management Centers, and Clinical Trials Units. Applications are due March 9, 2027.

Without published NOFOs, HIV researchers would have been unable to receive funding beyond December 2027. The delayed release froze the renewal process, led NIH to tell the networks to pause new trials, and threatened to dismantle decades of research infrastructure. For months, researchers could not submit applications,  while participants in ongoing trials faced the possibility of their participation in vital research being prematurely terminated. Because the networks run on seven-year funding cycles, every month of delay puts staff, research sites, and time-sensitive work on HIV cure, vaccines, maternal and pediatric care, and TB at risk. The future of the HIV clinical trials networks hung in limbo. Today’s publication of NOFOs are a result of two years of relentless work by TAG and our allies, alongside researchers and congressional staff behind the scenes, who all refused to allow four decades of scientific progress to collapse. 

“Millions of people living with HIV are alive because of research conducted over the past four decades by NIH-funded clinical trials networks. These networks, as well as the NIH as a whole, are the crown jewels of U.S.-funded science. Under this administration, these networks were at risk of extinction due to anti-science fanatics in high places. The networks can now survive to carry out essential science that will bring us closer to ending HIV by improving our options for prevention and treatment. Congratulations to the activists and the researchers who worked tirelessly to make this renewal possible. Our work isn’t done, and we’ll continue to ensure that the next steps lead to successful renewal of full funding for all four HIV networks,” said Mark Harrington, executive director of Treatment Action Group.

TAG, along with our allies from AIDS Action Baltimore and Save HIV Funding, has fought fiercely for the AIDS Clinical Trials Group (ACTG), the HIV Prevention Trials Network (HPTN), the HIV Vaccine Trials Network (HVTN), and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) since NIAID initially sought input on their future in 2025. We submitted recommendations to NIAID to continue all four networks. We told the Senate Appropriations Committee that withheld funds and procedural delays were a wrecking ball to lifesaving science. With Médecins Sans Frontières (MSF), we documented the threat to 39 research sites in South Africa. We demanded that NIH honor its legal and ethical obligations to thousands of trial participants. We published an advocacy toolkit with AVAC and HIVMA, cosponsored a Congressional briefing, and delivered comments to the AIDS Research Advisory Council (twice) calling for renewal of all four networks. Just last month, we urged Congress to demand the release of these NOFOs.

TAG will continue to monitor the renewal progress and advocate until full funding is secured for all four networks, including their vital international research sites.

About TAG
Treatment Action Group (TAG) is an independent, activist, and community-based research and policy think tank committed to racial, gender, and LGBTQ+ equity; social justice; and liberation, fighting to end HIV, tuberculosis (TB), and hepatitis C virus (HCV) for everyone, everywhere.

Back To Top